Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Generalized Epidermolysis Bullosa Simplex: early-phase trial registry

1 of 1 indexed Generalized Epidermolysis Bullosa Simplex trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Generalized Epidermolysis Bullosa Simplex: 1 US clinical trial tracked, 1 recruiting.

Generalized Epidermolysis Bullosa Simplex is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is TWi Biotechnology, running 1 of these trials.

Enrollment posture brief

Registry condition generalized-epidermolysis-bullosa-simplex

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Generalized Epidermolysi (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Generalized Epidermolysis Bullosa Simplex

Generalized Epidermolysis Bullosa Simplex lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Generalized Epidermolysis Bullosa Simplex on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Generalized Epidermolysis Bullosa Simplex is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on Generalized Epidermolysis Bullosa Simplex records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Vehicle Drug
1 trials
AC-203 Drug
1 trials

US sites by state

Facility locations filed on Generalized Epidermolysis Bullosa Simplex trials. A trial with sites in several states counts in each.

Texas 1 trials
South Carolina 1 trials
Ohio 1 trials
New York 1 trials
Illinois 1 trials
Florida 1 trials
Colorado 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Generalized Epidermolysis Bullosa Simplex page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Generalized Epidermolysis Bullosa Simplex trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • TWi Biotechnology sponsors the most Generalized Epidermolysis Bullosa Simplex trials on record, review their full trial history before evaluating a specific study. See TWi Biotechnology's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Generalized Epidermolysis Bullosa Simplex condition card totals 1 registered trials; most-linked intervention Vehicle; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.